Precision Spectra SCS Systems; Precision Novi SCS Systems; Precision Montage MRI SCS Systems; Spectra Wave Writer SCS Sy
Boston Scientific Corp · Decision date Sep 22, 2026
What did the FDA approve?
On 2026-09-22, FDA recorded an approval decision (APPR) for PMA supplement P030017/S399 from Boston Scientific Corp. The supplement is filed under the real-time process with the stated reason of a change to design, components, specifications or material. The recorded statement covers an alternate battery for the Charger devices SC-5312 and NM-5312, which the statement ties to Boston Scientific Spinal Cord Stimulation systems and Deep Brain Stimulation systems, respectively.
The supplement sits within the P030017 family, whose listed titles include the Precision Spectra, Precision Novi, Precision Montage MRI and Spectra Wave Writer SCS systems. The decision concerns the charger battery change, not a new approval of those systems. The product code is LGW, device category is a totally implanted spinal-cord stimulator for pain relief, and specialty is Neurology. The source gives no battery chemistry, performance data, or labeling changes, and no supporting documents are listed.
The record does not state whether the alternate battery affects charger compatibility, charging time, or service life, and no clinical or legal conclusion follows from the approval alone.
FDA approval order statement
approval for an alternate battery for the Charger devices SC-5312 and NM-5312 which are used with the Boston Scientific Spinal Cord Stimulation (SCS) systems and Deep Brain Stimulation (DBS) systems, respectively.
- Regulatory pathway
- PMA supplement
- Supplement type
- Real-Time Process
- Clinical specialty
- Neurology
- Decision date
- Sep 22, 2026
- FDA change category
- Change Design/Components/Specifications/Material
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- P030017/S399
- Regulatory pathway
- PMA supplement
- Applicant
- Boston Scientific Corp
- Product code
- LGW
- Decision code
- APPR
- Decision date
- Sep 22, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Stimulator, spinal-cord, totally implanted for pain relief.
- Applicant
- Boston Scientific Corp
- Product code
- LGW
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P030017. Subsequent supplements may change the device or its indications.
FDA decision timeline
P030017 · Original PMA
PRECISION SPINAL CORD STIMULATION(SCS) SYSTEM
P030017/S386 · Related supplement
Precision Spinal Cord Stimulator (SCS) Systems
P030017/S389 · Related supplement
WaveWriter Alpha Prime Spinal Cord Stimulation (SCS) Systems
P030017/S390 · Related supplement
Precision Spinal Cord Stimulator (SCS) Systems
P030017/S374 · Related supplement
WaveWriter Alpha Spinal Cord Stimulator (SCS) Mixed Systems, M8 Adaptor
P030017/S377 · Related supplement
Precision Spinal Cord Stimulator (SCS) Systems
P030017/S391 · Related supplement
Precision Spinal Cord Stimulator (SCS) Systems
P030017/S387 · Related supplement
Precision Spinal Cord Stimulator (SCS) Systems Introducer Hub Mold Change
P030017/S394 · Related supplement
Precision Spinal Cord Stimulator (SCS) Systems
P030017/S395 · Related supplement
Precision Spinal Cord Stimulator (SCS) Systems
P030017/S392 · Related supplement
Celestia Implantable Pulse Generator, Celestia External Trial Stimulator
P030017/S393 · Related supplement
Spinal Cord Stimulation (SCS)
P030017/S397 · Related supplement
Precision Spinal Cord Stimulator (SCS) Systems
P030017/S399 received
Application receipt date recorded by FDA.
P030017/S398 · Related supplement
Precision Spinal Cord Stimulator (SCS) Systems
P030017/S396 · Related supplement
WaveWriter Alpha and WaveWriter Alpha Prime SCS Systems; Celestia and Celestia Prime SCS Systems
P030017/S399 · FDA decision
Real-Time Process
Timeline entries are records held by MedtechLedger for P030017. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P030017
Explore the linked device profile
Other records with product code LGW
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| ABBOTT MEDICAL | PMA supplement | Oct 30, 2026 | FDA | |
| ABBOTT MEDICAL | PMA supplement | Oct 30, 2026 | FDA | |
| Medtronic Neuromodulation | PMA supplement | Oct 30, 2026 | FDA | |
| Medtronic Neuromodulation | PMA supplement | Oct 29, 2026 | FDA | |
| ABBOTT MEDICAL | PMA supplement | Oct 28, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
FDA describes the real-time supplement process as a review route for minor changes to a device, including certain design, software, sterilization or labeling changes.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Boston Scientific Corp
- Headquarters
- Not reported
- Brand website
- bostonscientific.com
- FDA applicant address
- 25155 Rye Canyon Loop, Valencia, CA, 91355
Sources and methodology
- Original FDA record: P030017/S399
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 20, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records






